nach oben

Clinical Pharmacokinetics

Erschienen in:

03.05.2019 | Review Article

Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline

verfasst von: Matthew W. McCarthy

Erschienen in: Clinical Pharmacokinetics | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

On 27 August, 2018, the US Food and Drug Administration approved eravacycline, a fluorocycline antimicrobial agent within the tetracycline class of antibacterial drugs, for the treatment of complicated intra-abdominal infections in patients aged 18 years and older. This decision was based on substantial clinical and pre-clinical data, including rigorous pharmacokinetic and pharmacodynamic work. This paper examines the in-vivo pharmacokinetic/pharmacodynamic work that led to the approval of eravacycline and explores how this important new antibiotic may be used to treat aggressive multidrug-resistant infections in the years ahead.

Xiao XY, Hunt DK, Zhou J, Clark RB, Dunwoody N, Fyfe C, et al. Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J Med Chem. 2012;55(2):597–605.CrossRef

Kang Y, Li Q, Mei L, Zhao H, Bai Y, Shen M, et al. Tetracycline resistance genes are more prevalent in wet soils than in dry soils. Ecotoxicol Environ Saf. 2018;156:337–43.CrossRef

Nelson KM, Viswanathan K, Dawadi S, Duckworth BP, Boshoff HI, Barry CE, et al. Synthesis and pharmacokinetic evaluation of siderophore biosynthesis inhibitors for Mycobacterium tuberculosis. J Med Chem. 2015;58(14):5459–75.CrossRef

Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother. 2015;59(3):1802–5.CrossRef

Sutcliffe JA, O’Brien W, Fyfe C, Grossman TH. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013;57(11):5548–58.CrossRef

Grossman TH, Starosta AL, Fyfe C, O’Brien W, Rothstein DM, Mikolajka A, et al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother. 2012;56(5):2559–64.CrossRef

Snydman DR, McDermott LA, Jacobus NV, Kerstein K, Grossman TH, Sutcliffe JA. Evaluation of the in vitro activity of eravacycline against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother. 2018. https://doi.org/10.1128/aac.02206-17.CrossRefPubMedPubMedCentral

Zhao M, Lepak AJ, Marchillo K, VanHecker J, Andes DR. In vivo pharmacodynamic target assessment of eravacycline against Escherichia coli in a murine thigh infection model. Antimicrob Agents Chemother. 2017. https://doi.org/10.1128/aac.00250-17.CrossRefPubMedPubMedCentral

Thabit AK, Monogue ML, Nicolau DP. Eravacycline pharmacokinetics and challenges in defining humanized exposure in vivo. Antimicrob Agents Chemother. 2016;60(8):5072–5.CrossRef

10.

Petraitis V, Petraitiene R, Maung BBW, Khan F, Alisauskaite I, Olesky M, et al. Pharmacokinetics and comprehensive analysis of the tissue distribution of eravacycline in rabbits. Antimicrob Agents Chemother. 2018. https://doi.org/10.1128/aac.00275-18.CrossRefPubMedPubMedCentral

11.

Connors KP, Housman ST, Pope JS, Russomanno J, Salerno E, Shore E, et al. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicrob Agents Chemother. 2014;58(4):2113–8.CrossRef

12.

Bassetti M, Vena A, Castaldo N, Righi E, Peghin M. New antibiotics for ventilator-associated pneumonia. Curr Opin Infect Dis. 2018;31(2):177–86.CrossRef

13.

Nation RL, Theuretzbacher U, Tsuji BT, International Society of Anti-Infective Pharmacology (ISAP). Concentration-dependent plasma protein binding: expect the unexpected. Eur J Pharm Sci. 2018;122:341–6.CrossRef

14.

Newman JV, Zhou J, Izmailyan S, Tsai L. Randomized, double-blind, placebo-controlled studies of the safety and pharmacokinetics of single and multiple ascending doses of eravacycline. Antimicrob Agents Chemother. 2018. https://doi.org/10.1128/aac.01174-18.CrossRefPubMedPubMedCentral

15.

Thabit AK, Monogue ML, Newman JV, Nicolau DP. Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis. Int J Antimicrob Agents. 2018;51(5):727–32.CrossRef

16.

Daoud Z, Farah J, Sokhn ES, El Kfoury K, Dahdouh E, Masri K, et al. Multidrug-resistant Enterobacteriaceae in Lebanese Hospital wastewater: implication in the one health concept. Microb Drug Resist. 2018;24(2):166–74.CrossRef

17.

Bathoorn E, Tsioutis C, da Silva Voorham JM, Scoulica EV, Ioannidou E, Zhou K, et al. Emergence of pan-resistance in KPC-2 carbapenemase-producing Klebsiella pneumoniae in Crete, Greece: a close call. J Antimicrob Chemother. 2016;71(5):1207–12.CrossRef

18.

Sheng ZK, Li JJ, Sheng GP, Sheng JF, Li LJ. Emergence of Klebsiella pneumoniae carbapenemase-producing Proteus mirabilis in Hangzhou, China. Chin Med J (Engl). 2010;123(18):2568–70.

19.

Newman JV, Zhou J, Izmailyan S, Tsai L. Mass balance and drug interaction potential of intravenous eravacycline administered to healthy subjects. Antimicrob Agents Chemother. 2019;63:3. https://doi.org/10.1128/aac.01810-18.CrossRef

20.

Roffey SJ, Obach RS, Gedge JI, Smith DA. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev. 2007;39(1):17–43.CrossRef

21.

Koulenti D, Song A, Ellingboe A, Abdul-Aziz MH, Harris P, Gavey E, et al. Infections by multidrug-resistant Gram-negative bacteria: what’s new in our arsenal and what’s in the pipeline? Int J Antimicrob Agents. 2019;53(3):211–24.CrossRef

22.

Thaden JT, Pogue JM, Kaye KS. Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence. 2017;8(4):403–16.CrossRef

23.

Zheng JX, Lin ZW, Sun X, Lin WH, Chen Z, Wu Y, et al. Overexpression of OqxAB and MacAB efflux pumps contributes to eravacycline resistance and heteroresistance in clinical isolates of Klebsiella pneumoniae. Emerg Microbes Infect. 2018;7(1):139.PubMedPubMedCentral

24.

Honore PM, Spapen HD. Eravacycline for treatment of complicated intra-abdominal infections: the fire is not ignited! Ann Transl Med. 2017;5(21):425.CrossRef

25.

Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, Tsai L, et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating Gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg. 2017;152(3):224–32.CrossRef

26.

Bassetti M, Righi E. Eravacycline for the treatment of intra-abdominal infections. Expert Opin Investig Drugs. 2014;23(11):1575–84.CrossRef

27.

Solomkin JS, Gardovskis J, Lawrence K, Montravers P, Sway A, Evans D, et al. IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs. meropenem in the treatment of complicated intra-abdominal infections. Clin Infect Dis. 2018. https://doi.org/10.1093/cid/ciy1029.CrossRefPubMedCentral

28.

Tripathi PC, Gajbhiye SR, Agrawal GN. Clinical and antimicrobial profile of Acinetobacter spp.: an emerging nosocomial superbug. Adv Biomed Res. 2014;3:13.CrossRef

29.

Mohammed N, Savardekar AR, Patra DP, Narayan V, Nanda A. The 21st-century challenge to neurocritical care: the rise of the superbug Acinetobacter baumannii: a meta-analysis of the role of intrathecal or intraventricular antimicrobial therapy in reduction of mortality. Neurosurg Focus. 2017;43(5):E8.CrossRef

30.

Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2018;51(1):62–4.CrossRef

31.

Raz-Pasteur A, Liron Y, Amir-Ronen R, Abdelgani S, Ohanyan A, Geffen Y, et al. Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: a retrospective matched cohort study. J Glob Antimicrob Resist. 2018. https://doi.org/10.1016/j.jgar.2018.12.001.CrossRefPubMed

32.

Zhang F, Bai B, Xu GJ, Lin ZW, Li GQ, Chen Z, et al. Eravacycline activity against clinical S. aureus isolates from China: in vitro activity, MLST profiles and heteroresistance. BMC Microbiol. 2018;18(1):211.CrossRef

33.

Poulakou G, Lagou S, Karageorgopoulos DE, Dimopoulos G. New treatments of multidrug-resistant Gram-negative ventilator-associated pneumonia. Ann Transl Med. 2018;6(21):423.CrossRef

34.

Mancini S, Kieffer N, Poirel L, Nordmann P. Evaluation of the RAPIDEC^® CARBA NP and β-CARBA^® tests for rapid detection of carbapenemase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis. 2017;88(4):293–7.CrossRef

Titel: Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline
verfasst von: Matthew W. McCarthy
Publikationsdatum: 03.05.2019
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 9/2019
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-019-00767-z

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2019

Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis

Assessment of Drug–Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials

Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib

Correction to: Clinical Pharmacokinetics of Atypical Antipsychotics: An Update

Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects